Alnylam Pharmaceuticals (NASDAQ:ALNY) Now Covered by Barclays

Barclays assumed coverage on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) in a research report report published on Wednesday morning, Marketbeat reports. The brokerage issued an overweight rating and a $527.00 target price on the biopharmaceutical company’s stock.

A number of other research firms have also weighed in on ALNY. HC Wainwright set a $570.00 price objective on Alnylam Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, November 4th. Jefferies Financial Group reduced their price target on Alnylam Pharmaceuticals from $550.00 to $549.00 and set a “buy” rating for the company in a research report on Thursday, October 30th. Wells Fargo & Company decreased their price target on Alnylam Pharmaceuticals from $479.00 to $376.00 and set an “equal weight” rating for the company in a report on Tuesday, January 20th. Stifel Nicolaus raised their price objective on shares of Alnylam Pharmaceuticals from $495.00 to $508.00 and gave the stock a “buy” rating in a research note on Thursday, December 11th. Finally, Leerink Partners decreased their target price on shares of Alnylam Pharmaceuticals from $370.00 to $351.00 and set a “market perform” rating for the company in a research note on Monday, December 15th. Twenty-two equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $485.21.

Alnylam Pharmaceuticals Stock Performance

ALNY opened at $349.58 on Wednesday. The company has a current ratio of 2.54, a quick ratio of 2.49 and a debt-to-equity ratio of 4.45. Alnylam Pharmaceuticals has a 12-month low of $205.87 and a 12-month high of $495.55. The firm has a 50 day moving average of $403.55 and a two-hundred day moving average of $424.01. The firm has a market capitalization of $46.18 billion, a PE ratio of 1,456.58 and a beta of 0.32.

Insider Transactions at Alnylam Pharmaceuticals

In related news, EVP Jeffrey V. Poulton sold 2,780 shares of the business’s stock in a transaction on Monday, January 12th. The shares were sold at an average price of $362.87, for a total value of $1,008,778.60. Following the completion of the sale, the executive vice president owned 57,465 shares of the company’s stock, valued at approximately $20,852,324.55. The trade was a 4.61% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Yvonne Greenstreet sold 9,577 shares of the stock in a transaction on Monday, January 12th. The shares were sold at an average price of $362.86, for a total transaction of $3,475,110.22. Following the transaction, the chief executive officer directly owned 78,411 shares in the company, valued at approximately $28,452,215.46. The trade was a 10.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 56,955 shares of company stock worth $24,072,733 in the last ninety days. Company insiders own 1.20% of the company’s stock.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Several large investors have recently bought and sold shares of ALNY. Root Financial Partners LLC purchased a new position in shares of Alnylam Pharmaceuticals in the third quarter valued at approximately $25,000. Salomon & Ludwin LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the third quarter worth approximately $27,000. Caitong International Asset Management Co. Ltd acquired a new position in Alnylam Pharmaceuticals in the 3rd quarter valued at $29,000. Ameriflex Group Inc. purchased a new position in Alnylam Pharmaceuticals in the 3rd quarter valued at $32,000. Finally, Aster Capital Management DIFC Ltd purchased a new position in Alnylam Pharmaceuticals in the 3rd quarter valued at $36,000. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.